Fig. 6: NRF2 is a transcription factor of RRM1-mediated malignant progression of melanoma. | Cell Death & Disease

Fig. 6: NRF2 is a transcription factor of RRM1-mediated malignant progression of melanoma.

From: MTCH2 regulates NRF2-mediated RRM1 expression to promote melanoma proliferation and dacarbazine insensitivity

Fig. 6

A–D Western blot and qPCR were used to detect the RRM1 expression levels in A375 and SK-MEL-21 cells treated with ML385 (NRF2 inhibitor) and Sulforaphane (NRF2 activator) for 24 h, then compared with the RRM1 protein (A, B) and mRNA levels in control cells (C, D). E, F Rescue to verify the interaction between RRM1 and NRF2 in A375 and SK-MEL-21 cells by using Western blot. G, H The cell proliferation rate was detected by MTS assay. I Consensus binding sites for NRF2 on the RRM1 promoter was analyzed by JASPAR database. J ChIP assay using NRF2 antibody and quantification of the enrichment of NRF2 binding to RRM1 promoter in A375 cells. K Design of luciferase reporter vector containing RRM1 promoter with a NRF2 binding site or a mutant NRF2 binding site. The red indicates mutant bases. L Luciferase reporter assay of NRF2 binding to RRM1 promoter. (The NRF2 group is treated with agonists). The data represent three independent experiments. Each bar represents mean ± SD. p values were calculated using a Student’s t test and multivariate analysis Of Variance (*p < 0.05, **p < 0.01, ***p < 0.001 vs. each control).

Back to article page